ESMO 2019 roundup

The European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma companies choosing it as a forum to reveal their latest studies.

AZ sells rights to gastro drug Losec to Cheplapharm in $309m...

AstraZeneca has agreed to sell most global commercial rights to its gastro drug Losec (omeprazole) and associated brands to Germany’s Cheplapharm Arzneimittel in a deal worth up to $309 mil

FDA rejection scuppers AZ’s hopes of a COPD triple clash wit...

The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by

ESMO 2019 – new data could unlock bigger market for PARP inh...

AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as first-l

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian...

The Pharma Comms Impact Conference - For Internal & External

20 Pharmaceutical Communications Senior Speakers, 1 Day